Generation Bio Inc. (GBIO) News

Generation Bio Inc. (GBIO): $5.55

0.14 (+2.59%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter GBIO News Items

GBIO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

GBIO News Highlights

  • GBIO's 30 day story count now stands at 3.
  • Over the past 5 days, the trend for GBIO's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • BIO and RARE are the most mentioned tickers in articles about GBIO.

Latest GBIO News From Around the Web

Below are the latest news stories about GENERATION BIO CO that investors may wish to consider to help them evaluate GBIO as an investment opportunity.

Generation Bio to Present at the 2022 Jefferies Cell and Genetic Medicine Summit

CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that the company will participate in a fireside chat at the 2022 Jefferies Cell & Genetic Medicine Summit on Thursday, September 29th at 10:30 a.m. ET in New York. A live webcast of the presentation will be available on the investor section of the company’s website at investors.generationbio.com.

Yahoo | September 22, 2022

Generation Bio Names Phillip Samayoa, Ph.D. Chief Strategy Officer

CAMBRIDGE, Mass., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced the promotion of Phillip Samayoa, Ph.D., to chief strategy officer. Dr. Samayoa has led strategy, corporate and portfolio development at Generation Bio since he joined the company in 2017, most recently serving as senior vice president. “Phillip has been instrumental in building a holistic strate

Yahoo | September 20, 2022

A number of insiders bought Generation Bio Co. (NASDAQ:GBIO) stock last year, which is great news for shareholders

When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...

Yahoo | September 17, 2022

Needham Thinks Generation Bio’s Stock is Going to Recover

In a report released today, Gil Blum from Needham reiterated a Buy rating on Generation Bio (GBIO – Research Report), with a price target of $23.00. The company's shares closed last Thursday at $8.05, close to its 52-week low of $3.96. According to TipRanks.com, Blum is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -15.5% and a 32.5% success rate. Blum covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Aeglea Biotherapeutics, and Rocket Pharmaceuticals. Generation Bio has an analyst consensus of Moderate Buy, with a price target consensus of $16.50, an 114.8% upside from current levels.

Brian Anderson on TipRanks | August 4, 2022

Generation Bio Co. (GBIO) Reports Q2 Loss, Misses Revenue Estimates

Generation Bio Co. (GBIO) delivered earnings and revenue surprises of -4.76% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | August 4, 2022

Generation Bio Reports Business Highlights and Second Quarter 2022 Financial Results

Cash balance of $312.2M expected to fund operations into 2025CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business highlights and second quarter 2022 financial results. “We are advancing our leading non-viral genetic medicine platform to unlock the potential of durable, redosable non-viral DNA therapeutics, and we have made significant progre

Yahoo | August 4, 2022

Generation Bio to Present at the 2022 Wedbush PacGrow Healthcare Conference

CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that the company will participate in a panel at the virtual 2022 Wedbush PacGrow Healthcare Conference on Tuesday, August 9th at 9:45 a.m. ET. A live webcast of the presentation will be available on the investor section of the company’s website at investors.generationbio.com. A replay will be avai

Yahoo | August 2, 2022

Generation Bio Appoints Dannielle Appelhans to Its Board of Directors

CAMBRIDGE, Mass., July 18, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced today that Dannielle Appelhans has been appointed to its Board of Directors. Dannielle Appelhans is a tenured pharmaceutical executive who has built deep expertise in strategy, manufacturing, supply chain and operations. She is currently the Chief Operating Officer of Rubius Therapeutics, where sh

Yahoo | July 18, 2022

Wall Street Analysts See a 174% Upside in Generation Bio Co. (GBIO): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 173.7% in Generation Bio Co. (GBIO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Yahoo | July 11, 2022

Generation Bio Announces Update to Its GMP Manufacturing Strategy

Company projects smaller GMP manufacturing footprint, enabled by further process development of rapid enzymatic synthesis of ceDNA at scale Company will seek to sublease its planned GMP facility, and will adopt a more capital efficient, modular, and flexible manufacturing approach Capital reallocated from facility buildout expected to extend cash runway into 2025 CAMBRIDGE, Mass., June 21, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medi

Yahoo | June 21, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5082 seconds.